Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-Label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer

Trial Profile

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-Label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Neo-ALTTO; NeoALTTO
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 09 Dec 2017 Results assessing association of circulating tumor DNA with response to neoadjuvent anti-HER2 targeted therapies, presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Dec 2017 Results assessing TRBV expression patterns response presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Dec 2017 Results investigating the relevance of copy number aberrations (CNAs) for pCR and event-free survival presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top